SSR181507, a Dopamine D2 Receptor Antagonist and 5-HT 1A Receptor Agonist. II: Behavioral Profile Predictive of an Atypical Antipsychotic Activity

Neuropsychopharmacology

Volumn 28, Issue 11, 2003, Pages 1889-1902

  Depoortere, Ronan ^a   Boulay, Denis ^a   Perrault, Ghislaine ^a   Bergis, Olivier ^a   Decobert, Michel ^a   Françon, Dominique ^a   Jung, Mireille ^a   Simiand, Jacques ^a   Soubrié, Philippe ^a   Scatton, Bernard ^a  

^a SANOFI   (France)

Author keywords

5 HT1A agonist; Antidepressant anxiolytic; Atypical antipsychotic; D2 antagonist

Indexed keywords

(3 EXO) 8 BENZOYL N [(7 CHLORO 2,3 DIHYDRO 1,4 BENZODIOXIN 1 YL)METHYL] 8 AZABICYCLO[3.2.1]OCTANE 3 METHANAMINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DEXAMPHETAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; SACCHARIN; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SL 88 0338; SSR 181507; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CATALEPSY; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; LOCOMOTION; MALE; MEMORY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; TASTE AVERSION; TRANQUILIZING ACTIVITY;

EID: 0242550590     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300261     Document Type: Article

References (44)

1. Barnes TR, Curson DA, Liddle PF, Patel M (1989). The nature and prevalence of depression in chronic schizophrenic in-patients. Br J Psychiatry 154: 488-491.
2. Balsara JJ, Jadhav JH, Chandorkar AG (1979). Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology 62: 67-69.
3. 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacology 15: 37-46.
4. Borsini F, Podhorna J, Marazziti D (2002). Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology 163: 121-141.
5. Broekkamp CLE, Oosterloo SK, Berendsen HHG, van Delft AML (1988). Effects of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine. Naunyn-Schmiedeberg's Arch Pharmacol 338: 191-195.
6. Buchanan RW, Kreyenbuhl J, Zito JM, Lehman A (2002). Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. Am J Psychiatry 159: 1035-1043.
7. Caldwell CB, Gottesman II (1990). Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 16: 571-589.
8. Casey DE (2001). Barriers to progress - the impact of tolerability problems. Int Clin Psychopharmacol 16(Suppl 1): S15-S19.
9. 1A receptor agonist. I: Neurochemical and electrophysiological profile. Neuropsychopharmacology submitted.
10. Csernansky JG, Schuchart EK (2002). Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 16: 473-484.
11. Costall B, Naylor RJ (1973). On the mode of action of apomorphine. Eur J Pharmacol 21: 350-361.
12. Christoffersen CL, Meltzer LT (1998). Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino) tetralin and its enantiomers. Neuropsychopharmacology 18: 399-402.
13. Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002). Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 28: 75-84.
14. De Vry J (1995). 5-HT1A receptor agonists: recent developments and controversial issues. Psychopharmacology 121: 1-26.
15. Ervin GN, Cooper BR (1988). Use of conditioned taste aversion as a conflict model: effects of anxiolytic drugs. J Pharmacol Exp Ther 245: 137-146.
16. Gillman PK (1999). The serotonin syndrome and its treatment. J Psychopharmacol 13: 100-109.
17. Goff DC, Midha KK, Brotman AW, McCormick S, Waites M, Amico ET (1991). An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 11: 193-197.
18. Goldman-Rakic PS (1994). Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci 6: 348-357.
19. Goodwin GM, De Souza RJ, Wood AJ, Green AR (1986). The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism. Psychopharmacology 90: 488-493.
20. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY (2001). 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76: 1521-1531.
21. Invernizzi RW, Cervo L, Samanin R (1988). 8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27: 515-518.
22. Kapur S (1996). 5-HT2 antagonism and EPS benefits: is there a causal connection? Psychopharmacology 124: 35-39.
23. 2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 50: 873-883.
24. Kleinlogel H (1982). The rat paradoxical sleep as a pharmacological test model. In: Herrmann WM (ed) EEG in Drug Research. Gustave Fisher: Stuttgart, pp 75-88.
25. Korsgaard S, Gerlach J, Christensson E (1985). Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur J Pharmacol 118: 245-252.
26. Liebman JM, Gerhardt SC, Gerber R (1989). Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction. Psychopharmacology 97: 456-461.
27. Meltzer HY (1999). The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21(2 Suppl): 106-115.
28. Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25: 233-255.
29. 1A receptors. J Pharmacol Exp Ther 295: 853-861.
30. Molewijk HE, Hartog K, van der Poel AM, Mos J, Olivier B (1996). Reduction of guinea pig pup isolation calls by anxiolytic and antidepressant drugs. Psychopharmacology 128: 31-38.
31. Moss LE, Neppe VM, Drevets WC (1993). Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol 13: 204-209.
32. Prinssen EP, Kleven MS, Koek W (1996). Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin. Psychopharmacology 128: 191-197.
33. Richelson E (1999). Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 60(Suppl 10): 5-14.
34. Roy A (1982). Risk factors for suicide in psychiatric patients. Arch Gen Psychiatry 39: 1089-1095.
35. Slater IH, Jones GT, Moore RA (1978). Inhibition of REM sleep by fluoxetine, a specific inhibitor of serotonin uptake. Neuropharmacology 17: 383-389.
36. Skarsfeldt T (1996). Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics. Psychopharmacology 124: 126-133.
37. Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C et al (2001). Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158: 1722-1725.
38. Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Uehara T, Kurachi M et al (2000). Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol 20: 386-388.
39. Tajima O (2001). Mental health care in Japan: recognition and treatment of depression and anxiety disorders. J Clin Psychiatry 62(Suppl 13): 39-44.
40. Wadenberg ML, Ahlenius S (1991). Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Transm [Gen Sect] 83: 43-53.
41. Wadenberg ML, Hicks PB (1999). The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Behav Rev 23: 851-862.
42. Wadenberg ML, Kapur S, Soliman A, Jones C, Vaccarino F (2000). Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology 150: 422-429.
43. Wegener G, Smith DF, Rosenberg R (1997). 5-HT1A receptors in lithium-induced conditioned taste aversion. Psychopharmacology 133: 51-54.
44. Yoshida K, Sugita T, Higuchi H, Hishikawa Y (1998). Effects of tandospirone on tardive dyskinesia and parkinsonian symptoms. Eur Psychiatry 13: 421-422.